Autonomous Medical Care for Exploration Class Space Missions by Smart, Kieran et al.










1- Wyle Life Sciences, Houston, Texas 
2- Nasa Medical Operations and Healthcare Systems 
 
 





The US-based health care system of the International Space Station (ISS) contains several 
subsystems, the Health Maintenance System, Environmental Health System and the 
Countermeasure System.  These systems are designed to provide primary, secondary and tertiary 
medical prevention strategies.  The medical system deployed in Low Earth Orbit (LEO) for the 
ISS is designed to enable a “stabilize and transport” concept of operations. In this paradigm, an 
ill or injured crewmember would be rapidly evacuated to a definitive medical care facility 
(DMCF) on Earth, rather than being treated for a protracted period on orbit.   
The medical requirements of the short (7 day) and long duration (up to 6 months) 
exploration class missions to the Moon are similar to LEO class missions with the additional 4 to 
5 days needed to transport an ill or injured crewmember to a DCMF on Earth. Mars exploration 
class missions are quite different in that they will significantly delay or prevent the return of an 
ill or injured crewmember to a DMCF. In addition the limited mass, power and volume afforded 
to medical care will prevent the mission designers from manifesting the entire capability of 
terrestrial care. NASA has identified five Levels of Care as part of its approach to medical 
support of future missions including the Constellation program. In order to implement an 
effective medical risk mitigation strategy for exploration class missions, modifications to the 
current suite of space medical systems may be needed, including new Crew Medical Officer 
training methods, treatment guidelines, diagnostic and therapeutic resources, and improved 
medical informatics.   
  
 Introduction 
The US-based health care system of the International Space Station (ISS) contains several 
subsystems, the Health Maintenance System, Environmental Health System and the 
Countermeasure System.  These systems are designed to provide primary, secondary and tertiary 
medical prevention strategies (see table 1) for the Crewmembers. 
The bulk of the risk mitigation for medical maladies in LEO is placed on preventive 
medicine, as opposed to treatment. For ISS Operations two crewmembers are selected as Crew 
Medical Officers (CMOs) to receive 40 hours of dedicated training in the use of the on-orbit 
medical hardware and have the opportunity of additional ‘hands on’ training in an emergency 
and surgical operating room. For Shuttle two crewmembers are selected, by the Commander of 
each flight, to be CMOs. These crewmembers receive 18 hours of dedicated training in the use of 
the Shuttle medical equipment for the treatment of many types of illness and injury.  The medical 
system deployed in Low Earth Orbit (LEO) for the ISS is designed to enable a “stabilize and 
transport” concept of operations. In this paradigm, an ill or injured crewmember would be 
rapidly evacuated to a definitive medical care facility (DMCF) on Earth, rather than being treated 
for a protracted period on orbit.   
 
Insert table 1 approximately here 
 
The medical requirements of the exploration class missions to the Moon are similar to 
Low Earth Orbit (LEO) class missions with the additional 4 to 5 days needed to transport an ill 
or injured crewmember to a DCMF on Earth.  Mars exploration class missions are quite different 
in that they will significantly delay or prevent the return of an ill or injured crewmember to a 
DMCF. In addition the limited mass, power and volume afforded to medical care will prevent the 
mission designers from manifesting the entire capability (personnel and hardware) of a terrestrial 
DCMF (see table 2).  In order to implement an effective medical risk mitigation strategy for  
exploration class missions the use of a preventive strategy is the single most important method to 
reduce risk.  In addition several changes to the current suite of space medical systems are 
necessary, including new training practices for CMOs, treatment guidelines, diagnostic and 
therapeutic resources, and improved medical informatics.   
  
 Insert table 2 approximately here 
 
Our current medical capabilities in support of ISS space crew represent a significant 
increase in medical compared to the Mercury, Gemini, Apollo, Shuttle, and Mir programs.  A 
higher level of care is possible due to our increase in experience applying medical prevention 
strategies toward spaceflight induced changes in physiology and pathophysiology. Advances in 
terrestrial screening and preventive medicine allow disease processes to be identified early, 
mitigated for flight certification or screened out of the astronaut population.  
 
Medical Care Mars Mission Requirements  
The current mars exploration mission timeframe permits the phased development of a 
medical capability to meet the demands future deep space missions.  In 2020 the first lunar 
missions are planned to deliver four astronauts to the surface of the Moon for short periods of 
time at the polar regions. Surface stays will gradually increase from two weeks to several months 
with the aim of establishing a permanent Lunar base with rotating crews in 2024, and a fully 
pressurized rover vehicle in 2027.  NASA views the permanent lunar base as part of the critical 
path to accomplishing the validation and testing of the technology needed to explore Mars for 
surface stays of one year duration.  The ability to rapidly evacuate a crew to Earth from the moon 
is possible should a catastrophic failure occur during the mission, however, this is not the case 
for a Mars mission once a transit vehicle leaves LEO. NASA is currently developing the 
Constellation (exploration) medical requirements, which will define the medical capabilities of 
the Crew Exploration Vehicle (CEV), Lunar Surface Access Module (LSAM), and the 
permanent Lunar Base. 
  
 The following list provides examples of high level medical mission requirements which 
could be used determine the design of medical resources for an Expeditionary Mars Mission.   
 
1. Fundamental mission priorities (in descending order of importance):  
a. immediate health and safety of the crew as a whole  
b. immediate health and safety of an individual crewmember 
c. long term health and safety of the crew as a whole 
d. long term health and safety of the individual crewmembers 
e. mission success 
 
2. Mars surface stay will not exceed 400 days . 
3. During a medical contingency on any exploration class mission, all 
medical resources will be available and functional.   
4. Medical system capabilities mitigate the likelihood and/or severity of 
medical events based on a “best evidence” medical analysis 
techniques where possible. 
5.  Medical care for crewmembers includes primary and secondary prevention to 
mitigate the deleterious pathophysiological and behavioral health and 
performance effects of long duration space mission. 
6. Dedicated mission control based flight surgeons shall provide 
telemedicine medical support during flight and bedside medical care 
during preflight and post flight mission phases. 
7. For a Mars Mission there shall be at least one physician in the crew.  
8. There will be only one seriously ill or injured crewmember per medical 
event.   
9. There will not be continuous communication between the mission and the 
Earth support team, and as distance from Earth increases so will latency in 
communication.  As a result, the crew shall be trained and equipped to 
provide autonomous medical care.  
10. The lack of DCMF resources and the inability to immediately return to Earth 
during a Mars mission will increased the risk morbidity or mortality from 
illness and injury.   
  
 Occupational Medicine Prevention Strategies Applied to Exploration Class Missions 
The approach to the care of a crewmember on an exploration mission follows the accepted 
pattern of Primary, Secondary and Tertiary intervention. (see Table 3).  Therefore the 
occupational medicine approach of preventing illness and injury is focused on reducing the 
likelihood and/or severity of medical events occurring, or in other words, controlling a ‘medical 
hazard’.  This is usually accomplished by applying mitigation strategies or hazard controls to risk 
factors, where risk is defined as the likelihood of a medical event occurring with a certain 
severity.  Humans are protected medically in extreme environments by taking a preventative 
approach to illness and injury, using progressive addition of levels of prevention (Primary, 
Secondary and Tertiary levels of care) until the risk is considered adequately mitigated by the 
mission designers.   
 
Insert table 3 approximately here 
 
The medical capability designed into any space mission should be focused at reducing the 
likelihood or severity of a medical event. For example, the risk of Acute Myocardial Infarction 
(AMI) is managed by applying primary and secondary prevention toward mitigating the risk 
factors of AMI, such as selection of crewmembers with low coronary artery calcium (CAC), low 
Framingham Risk scores (FRS), and by providing astronauts with the means to maintain 
cardiovascular fitness in reduced gravity environments.  The medical prevention model therefore 
aims to reduce the risk by reducing its occurrence (likelihood or incidence) and/or impact 
(severity).  The clinical presentation of AMI in the form of sudden cardiac death, myocardial 
infarction, unstable angina and most life threatening arrhythmias will cause an abrupt 
incapacitation or significant impairment of crewmember performance.2,17,20 9,21  AMI may result 
in  the loss of life or mission, and therefore reducing its likelihood through appropriate primary 
and secondary prevention is the most effective mission enabling strategy.  
The use of tertiary prevention to treat illness or injury is generally considered an 
emergency treatment and therefore not a desired means of managing medical events. Tertiary 
prevention should only be manifested on the vehicle under those circumstances where the 
incidence and severity of the medical hazard are high enough that it cannot otherwise be 
  
managed.  This strategy involves a careful balance between the amount of risk the Agency and 
mission designers are willing to accept and the resources needed to reduce overall mission risk.   
 
Prevention strategies to reduce the risk of idiopathic illness  
The prediction of sub-clinical disease in a healthy cohort and its outcome with appropriate 
primary and secondary prevention is very difficult, even in populations where we have extensive 
experience. Predicting the incident and prevalence of disease in these healthy cohorts makes the 
Mars mission medical care system requirement definitions challenging to develop.   
 
Example 1 Acute Myocardial Infarction versus Cancer: 
The risk data derived from the analysis methods used by Gillis et al8 is encouraging when 
applied to diseases like AMI since it estimates the incidence of 1 AMI induced sudden cardiac 
arrest every 33,000 person years for an astronaut analog subgroup with no CAC and a low FRS 
compared to an age matched population of 40 – 65 years.3,11  The prevention of AMI by 
significantly reducing the prevalence of CAD in the astronaut corps seems to drive the overall 
risk of sudden cardiac death to mission acceptable levels. 
With Cardiac risk becoming so low other risks may now become predominate in the 
mission design. Cardiac risk has now become very small when compared to, for example, the 
annual risk of cancer in the standard US population, reported by the National Cancer Institute16 
(age 20 to 54) being approximately 200 per 100,000 person years (or approximately 1 for every 
625 person years or 0.6%/person/Mars mission).  The approximate risk of breast and prostate 
cancer is 1 in 1,500 and 3,300 person-years respectively in this young cohort16.  Both of these 
cancers are difficult to screen in young and middle aged astronaut populations and would have a  
significant impact on any long duration mission.  With the expected 5 year cancer survival 
outcomes exceeding the 5% survival of a sudden cardiac arrest, in contrast to AMI, there is the 
possibility to effectively treat many cancers with chemo-therapy during a Mars mission,  Breast 
cancer is the most common non-skin malignancy diagnosed in women and is the leading cause of 
cancer-related mortality in women aged 20-59 years.1,7,12,19  The increased genetic susceptibility 
mainly from BRCA1 and BRCA25 genes, are risk factors which can also be selected out of an 
astronaut population.   
 
  
Example 2 Spontaneous Pneumothorax: 
The risk of spontaneous pneumothorax (SP) in the general population requiring hospital 
admission or physician consultation was published by Gupta et al10, with rates generally reaching 
1 per 5,000 person years in the typical age groups found in the astronaut corps (30 to 50 years).  
This low incidence of spontaneous pneumothorax in this cohort likely reflects the upper limit of 
risk for astronauts.  
 
Prevention strategies to control occupationally induced medical events 
The outcomes of idiopathic disease during space flight can be roughly estimated by 
observing incidence and response to treatment in analog populations, however this can be 
complicated by the limited treatment available during a space mission.  The maintenance of 
human performance is influenced by the environment though air quality (headache – toxins or 
maladjusted atmospheric mixture), water and food quality (gastrointestinal distress – 
contaminated food or water system), radiation (degradations in the immune system and 
gastrointestinal distress), psychological factors (depression from crew interaction issues or news 
from Earth), and many other physiological, physical, and cognitive factors.  Small changes in 
several of these factors may have a compounding effect and cause significant mission impact as 
they manifest as medical events.  Many of these environmental factors may require secondary 
prevention in the form of countermeasures.   
 
Example 3 Occupationally Induced Pneumothorax  
Astronauts undergo a rigorous selection physical exam and are exposed to significant 
atmospheric changes during training which would most likely uncover a predisposition to 
pneumothorax further reducing the chance of a SP occurring during a mission.  The only 
plausible risk factor for SP in reduced gravity space exploration environments is acute hypobaric 
exposure, such as during an EVA, which if it occurred would present a significant challenge to 
the CMO both in diagnosis and immediate treatment.  
 Thoracic injuries account for almost 25% of all trauma deaths; most of these injuries can 
be adequately treated by chest drainage with a tube thoracostomy alone18.  Rib fracture is the 
most common thoracic injury and is present in at least 10% of all traumatic injuries of the thorax 
and in almost 40% of patients who sustain non-penetrating blunt trauma13. While rib fractures 
  
can produce significant morbidity and mission impact, the diagnosis of associated complications 
(such as pneumothorax, hemothorax, pulmonary contusion, atelectasis, flail chest, cardiovascular 
injury, and injuries to solid and hollow abdominal organs) may have a more significant clinical 
impact. Misthos et al13 found that of 709 patients with a history of blunt thoracic injury who did 
not meet the criteria for intra-hospital management, almost 10% developed delayed 
pneumothorax 2 to 14 days later.  Of these delayed pneumothorax 81% required chest tube 
thoracostomy.  The low impact nature of blunt chest trauma most likely encountered during 
space missions might cause pneumothorax to present in a similar fashion.     
 
Example 4 Treatment of Pneumothorax in Space 
The management of pneumothorax on the ISS or the moon would require a tube 
thoracostomy which is presently considered a mission-terminating event.  Should the treatment 
of SP or pneumothorax secondary to minor blunt trauma or hypobaric exposure become a 
requirement for exploration class missions, the insertion of a chest tube by the CMO will be a 
necessary component of medical care , which in the case of  a  Mars Mission will likely be a 
physician  Under most circumstances, the morbidity of a tube thoracostomy usually outweighs 
the risk of untreated pneumothorax, and although a moderate pneumothorax is generally not 
acutely life threatening, a delay in diagnosis and treatment may eventually result in respiratory 
and circulatory collapse.  Therefore the risk of a catastrophic, trauma induced thoracic injury in 
reduced gravity environments are very low, with on-board ultrasound serving as an effective tool 
in establishing the diagnosis, treatment, and return to duty status of an injured crew member. 
Example 5 Decompression Sickness: 
The risk of decompression sickness (DCS) during an ISS or Shuttle extravehicular activity 
(EVA) is considered to be adequately controlled by breathing 100% oxygen for an appropriate 
time prior to exposing the astronaut to reduced barometric pressures.  Should the risk of DCS 
become unacceptable for exploration class missions, different prevention strategies may need to 
be applied to other DCS risk factors.  In addition, should the mission designers decide that the 
risk of DCS is uncontrolled despite the optimization of all possible risk factors using primary and 
secondary prevention, tertiary prevention in the form of emergency hyperbaric therapy may need 
to be designed into the mission.  Since some forms of DCS will incapacitate a crew member and 
  
require ALS, a hyperbaric chamber with advanced critical care may be needed.  There are 
alternative DCS treatments which can be manifested, such as using the spacesuit itself as a 
“partially pressurized” hyperbaric chamber however this treatment presently cannot provide the 
equivalent standard of DCS therapy used on Earth.  
 
Example 6 Radiation: 
The risk of a fatal dose of radiation has always been a concern of the space program and 
acute radiation sickness has always been considered an uncontrolled hazard for Lunar and Mars 
surface EVA.6  Recent data has shown that during a 180 day lunar surface mission performing 65 
EVAs, the incidence of very large Solar Particle Events (SPE) with maximal doses of 
approximately 1 Gray to blood forming organs is between 0.2 to 0.3 % .4  This calculation 
assumes that the crew will be exposed for the 3 hours it will take to get back to the pressurized 
habitat module.  An acute dose of 1 Gray will not pose a life threatening risk to the crew in the 
form of acute radiation sickness with bone marrow suppression, but may cause some prodromal 
symptoms (> 10% probability, presenting as nausea and emesis).4  This represents a significant 
reduction in the severity of the effects of an SPE on a crew performing an EVA on the lunar 
surface as compared to what was previously believed.  The lunar EVA presents a much higher 
radiation risk compared to Martian EVAs due the greater distance from the sun and atmospheric 
attenuation.  The acute radiation event however does not address the increase risk of long term 
carcinogenesis effects of the individual. 
 
Which Medical Conditions could be disqualifying? 
Even the most common and treatable illness and/or injury become a challenge in extreme 
environments such as those found during space travel and planetary exploration.  The challenge 
for Space Medicine is to determine the selection criteria and performance requirements of 
crewmembers for a lunar or Mars Mission.   Examples of crewmembers which may not be 
considered for selection for a Mars Mission might be candidates who: 
 
1. Have chronic conditions that require regular dosing of life-sustaining medication for the 
purposes of secondary or tertiary prevention (i.e. thyroid hormone replacement or 
anticoagulation). 
  
2. Have conditions that will be worsened by spaceflight exposure, placing them at 
additional personal health risk though not necessarily increasing mission risk (i.e. 
previous radiation exposure or preflight osteopenia/osteoporosis)  
3. Require specialized medical devices for monitoring or treatment of a medical condition, 
including conditions that require special provisions to conduct routine required 
countermeasure activities (i.e. blood glucose meter or heart rate monitor). 
4. Have a disease or requires treatment for same, and for which the effects of space travel 
may be deleterious to the short or long term health of the individual.  
5. Have medical risk factors which raise individual or mission risk to unacceptable levels ( 
i.e elevated CAC scores, genetic markers for neoplasia) 
6. Have a medical condition which would prevent participation as a candidate in any 
scientific and medical operational research studies, as their underlying condition would 
confound the collected data. 
 
One class of candidates the previous list does not include is the crewmember requiring 
primary prevention to manage a chronic condition which does not pose an increase in mission 
risk.  These chronic disease risk factors are being mitigated in a manner which makes them 
acceptable to the civilian and military aviation community as well as long duration ISS 
crewmembers.  The question remains “which diseases when combined with their primary 
prevention strategies will present an acceptable risk for a lunar or Mars Missions?” 
 
Levels of Care 
In the 1980’s NASA wrote its first version of the Manned Systems Integration Standard (MSIS), 
which specified how to design systems to support human health, safety, and productivity in space 
flight. However, this was too specific towards existing space programs and NASA recently 
decided to write a set of human factors and medical standards using more general terms that 
would apply to all present and future systems with human crews. The result is an agency-level 
two-volume document that addresses the human needs for space flight, called the NASA Space 
Flight Human Systems Standards. Volume 1, “Crew Health”14 covers the requirements needed to 
support the astronaut health and Volume 2, “Habitability and Environmental Health”15 covers the 
requirements for a system design that will maintain astronaut safety and performance . 
 
NASA has as part of this process defined five levels of medical care to address medical 
support for Exploration Missions ranging from LEO missions of less than 8 days to a Mars 
Expedition Mission lasting several years. (See table 4) These levels of care identify the types of 
  
medical threat faced by crewmembers and the interventions needed to address those concerns. 
The levels focus on classes of missions, ranging from Level 1 which would be LEO missions to 
the ISS, and Level 5 which refers to Mars-type exploration class missions.  
Mass, power, and volume constraints for Mars missions are significant:  i.e., a ten pound 
piece of medical equipment could require 400 pounds of Earth launch mass (vehicle structure, 
propellant, etc.) for a long duration Mars mission. The launch phase for return from distant 
exploration destinations are, pound for pound of mass, even more challenging.  (See figure 1) 
 
Insert figure 1 approximately here 
 
NASA recognizes that there is a significant risk that crewmembers may have a serious 
medical event during a mission an exploration class missions, and the fifth level of care was 
designed specifically to address this challenge. Space Flight Human Systems Standards 
documents the need for preventive strategies to mitigate risk factors and adequately control 
medical hazards, but also provides treatment capability for any critical or catastrophic medical 
event that is reasonably expected to occur. The standards also document that, in a Mars 
exploration mission, extensive medical training is required which can be met with the addition of 
a specially trained physician to the crew compliment. 
NASA Levels of Care (see figure 2) describe the 3 categories of tertiary prevention, which 
are broadly categorized into 3 areas: 
1. Advanced Life Support 
2. Transitional Care 
3. Ambulatory Care.   
 
These tertiary prevention treatment capabilities are required for Mars missions to bring 
major and minor medical events to some form of medical stability to ensure mission success.  
The integration of all levels of prevention will describe the requirements for the total mass, 
power, volume, and training (MPVT) needed to reduce overall medical mission risk to an 
acceptable level.  A Mars mission will need significant MPVT to support primary and secondary 
prevention (exercise countermeasures, environmental monitoring, etc.) and tertiary prevention 
(resuscitation, acute and chronic treatment, etc) for major/ minor illness or injury.  An ISS LEO 
mission requires little tertiary prevention MPVT due to its evacuation capability to Earth and the  
  
secondary prevention (countermeasures) MPVT is also minimal because faulty equipment can be 
replaced with regular re-supply.   
 
Advanced Life Support Care: 
The Society of Critical Care Medicine and the Institute of Critical Care Medicine, defines 
the requirement for “critical care” (also known as “advanced life support” care) for cases in 
which a patient’s life is in jeopardy or is at risk of sustaining failure of one or more organ 
systems.1 These patients require constant, intensive care, including continuous physiological 
monitoring over a period of time.  Tertiary prevention also requires “emergency care” which 
refers to the care needed in the immediate aftermath of an illness or injury but does not 
encompass the sustained care provided to these patients in the ensuing hours or days.  
In terrestrial settings, “critical care” or “advanced life support” (ALS) is generally 
provided in intensive care units (ICUs) by specialist caregivers such as physicians with critical 
care training, critical care nurses, respiratory therapists, etc..  Although different hospitals have 
different criteria for ICU admission, based upon the hospital’s size, staff, and capabilities, 
common criteria include: 
• Use of a ventilator or other respiratory support  
• Unstable vital signs (as defined by the attending physician or nurse) 
• Need for close medical supervision  
• Use of drug infusions (drug specifics vary by hospital but may include anti-
dysrhythmics and/or pressor agents)  
• Recent or anticipated use of defibrillator, cardioversion, or transcutaneous pacing 
• Multi-organ system failure 
 
Examples of conditions which might be categorized as requiring ALS for spaceflight will 
includes severe infection, toxic inhalation, 3rd degree thermal burns, anaphylaxis, DCS etc..  Risk 
factors underlying events which require ALS should be controlled by proper mission design and 
effective primary and secondary prevention strategies.   
The major medical challenge to designing a mission to Mars is the inability to return a 
crewmember to DMCF. Therefore, mission designers need to consider the consequences of 
                                                 
1 Society of Critical Care Medicine website, “About Critical Care Medicine”, 
http://www.sccm.org/about/about.html, and Institute of Critical Care Medicine website, “The Institute’s Story”,  
http://www.911research.org/intro.html . 
  
treating certain illnesses and injuries from which the crewmember may not survive or more 
importantly, will survive, and which could deplete irreplaceable consumables and place the 
remaining crew at additional risk. It may be possible to resuscitate or stabilize a crewmember 
with a significant medical insult, however if they require ventilation or fluids without the 
possibility of return to a DMCF, consideration must be given as to whether initializing or 
sustaining treatment under such circumstances is ethically appropriate and mission enabling.  
Unfortunately the primary medical provider in the crew may need to make such an autonomous 
decision, real-time with incomplete data and limited resources.  
 
Transitional Care 
For exploration class missions, “transitional care” is needed for those conditions which 
impair the crewmember’s ability to perform his or her scheduled tasks, yet are not so 
incapacitating as to require ALS. These conditions do not need continuous, close observation but 
do require care beyond what the crewmember can self administer. Transitional care may also be 
required for the period after ALS until full recovery. 
Criteria for “transitional care” would include: 
• Provision of intermittent parenteral medication, such as 
intramuscular or intravenous injections 
• Use of a splint or other device that limits mobility or activity 
level 
• Assistance with the activities of daily living, such as 
catheterization in order to void 
• Inability to perform the majority of scheduled mission tasks  
• Inability to maintain a normal nutritional status. 
• Need for intermittent physiological monitoring and/or 
assessment 
• Need for frequent private medical or psychological conferences 
 
Examples of conditions which might be categorized as requiring transitional care would 
include: diverticulitis, kidney stone, severe gastroenteritis, abdominal pain (of unknown 
etiology), or a fractured wrist.  Obviously, many medical maladies which require transitional 




For exploration class missions, “ambulatory care” is defined as that level of medical care 
which a crewmember can independently self administer.  While the flight surgeon on Earth 
might be consulted, no complex interventions or assistance from other crewmembers are needed.  
The majority of conditions which require ambulatory care are minor ailments which would be 
likely to resolve eventually even in the absence of treatment, but may in the interim have 
significant mission impact. 
Criteria for “ambulatory care” are defined as:  
• Resolution expected with the administration of oral or topical medications 
• No more than one procedure required for resolution of condition (example: single 
dose of intravenous medication or reduction of dislocation) 
• Ability to perform the majority of scheduled mission tasks 
 
Examples of conditions which might be categorized as requiring ambulatory care would 
include: abrasion, rash, frostnip, or upper respiratory infection. 
 
Duration of therapy 
Ideally, provision of the appropriate level of care during an exploration mission will 
resolve a condition; either completely or to the point that it requires a less intensive level of care.  
The following durations of care for Mars missions need to be defined for all probable medical 
illnesses or injuries requiring treatment: 
1.) Number of hours/days of ALS care capability 
2.) Number of days of transitional care capability 
3.) Number of days of ambulatory care capability 
 
Given that the crewmembers are presumed to be in good health prior to the inciting injury or 
illness, it is anticipated that after a short period of critical care, the crewmember’s condition will 
improve and only transitional care will be required.   A Lunar mission may require an ALS 
capability to sustain the life of a crew member for the length of time it takes to return to a DCMF 
on Earth.  This represents a significant MPVT for any Lunar short or long duration mission. 
Therefore ALS care should be provided for a limited period of time with subsequent triage to 
  
determine whether additional resources are needed, or whether the intervention should be 
terminated.  
 
In addition, ALS care should be able to: 
• improved diagnosis – more time to follow signs and symptoms and to perform the 
available diagnostic tests, as well as time to create and consult with an earth-based 
team of medical specialists with the appropriate knowledge base(s) 
• provide a trial-of-therapy – the ability to attempt treatment and to observe the 
crewmember’s response 
• improved patient outcome through more accurate diagnosis  
• optimize the balance between patient outcome and mission impact 
 
In the event that provision of ALS care allows the crewmember to improve sufficiently 
such that transitional care is subsequently required, resources will be required to support 
transitional care resolution of the original medical condition, plus resources to manage any 
secondary complications. Although it is conceivable that some conditions might require 
transitional care for an extended period, the goal of treatment is to improve the condition, and it 
is therefore reasonable to assume that with appropriate care most conditions will shift from 
requiring transitional care to needing only ambulatory care.   
An ambulatory level of care would be available for the duration of the mission.  This is 
meant to address not only conditions that had been more serious but are improving, but also the 
routine minor conditions that are frequently encountered, which, given adequate supplies, can 
safely be managed permanently or treated to resolution in-flight. ISS experience has shown that 
the most common conditions seen during missions have been self-limiting illnesses and chronic 
problems which only require an ambulatory level of care. 
The occurrence of illness or injury during an exploration mission may result in several 
outcomes depending on the patient’s response to therapy.  The ability to predict how any 
particular illness or injury will progress from ALS care through ambulatory care is quite difficult 
on Earth, and the unique characteristics of a Lunar or Mars mission may further complicate this 
task.  There may be insufficient data to drive an illness or injury specific model, yet a 
generalized approach may not identify essential requirements for specific medical events. A 
comprehensive risk analysis of all possible medical hazards would be one approach to drive the 
definition of exploration class medical systems. 
  
 Failure of Therapy 
The possibility of permanent impairment or death exists during any remote mission to an 
extreme environment and exploration missions are no different.  Accordingly, it is necessary to 
prospectively identify procedures to be followed in such a case.  This is important so that all 
stakeholders (flight surgeons, crew and families, flight directors, public affairs, etc.) are familiar 
with procedures in the event of a death.  Similarly, the criteria for a considering a “do not 
resuscitate” status on a fatally ill or injured crewmember should be established prospectively for 
all possible medical conditions during a Mars mission.   
In addition, criteria should be established prospectively for those conditions for which 
descent to the Martian surface for one year is inappropriate.  This could include those conditions 
which are intolerant of the necessary seat position, the G forces (including descent and impact), 
other forces (spin, swing, etc.), or those which have a need for continual assessment and/or 
intervention which may embarrass mission success.  Some examples of these conditions, albeit 
very rare for a Lunar or Mars mission, include spinal injury, femur fracture, or cardiovascular 
compromise. 
 
Engineering Requirements for Space Medical Hardware and Procedures  
All space flight hardware is designed, manufactured, tested and certified to meet its mission 
critical functional requirements.  In addition the hardware can’t be easily returned to Earth for 
upgrades, repair, or replacement.  Due to the challenges imposed by the requirement for 
autonomous medical care, coupled with the limited MPVT associated with a Mars mission, a 
requirement for advance medical technologies which have no Earth medical analog may need to 
be developed by NASA.  An example of this is the promising recent work funded by NASA’s 
Smart Medical Systems project  to validate closed-loop algorithms used to control 
oxygenation/ventilation and fluid resuscitation in an acutely ill patient which represents a change 
the current paradigm for medical care in extreme environments.  The paradigm shifts in medical 
policy require that:  
• certain aspects of medical care for the patient be adequately managed by the medical 
device in question in an autologous fashion with minimal physician oversight.  
  
• the use of these algorithms minimizes the consumption of critical mission resources 
(such as fluids or oxygen) by optimizing what is medically needed for medical event 
stabilization.  
The provision of a reasonable and prudent duration of ALS for a Mars Mission would require the 
following resources be manifested: 
• A means of securing and maintaining the airway 
• A means of oxygenating and ventilating the patient 
• A means for the patient to resume unassisted respiration 
• A dedicated location for the provision of medical care and ready access to other 
requisite resources 
• A means of providing continuous physiological monitoring 
• Adequate supplies of pharmaceuticals, including anti-dysrhythmics, fluids, systemic 
and local analgesics, sedatives, and antibiotics, any of which can be administered 
parenterally or orally 
• A means of providing parenteral medications at specific rates (such as syringe drivers 
or infusion pumps) 
• A means to relieve a hemo-pneumothorax, effusion, or pericardial tamponade 
• A means of emptying the stomach, colon and bladder 
• A means to stop external bleeding, protect wounds, and promote their healing 
• Adequate pre-flight training of the crew medical officer (CMO) in the requisite skill 
sets, with sustainment training during the mission 
• Diagnostic imaging system(s) 
• The ability to perform basic laboratory studies 
• Digital scopes (stethoscope, ophthalmoscope, otoscope) that permit downlink of 
images and/or sounds  
• The ability to splint or otherwise stabilize orthopedic injuries  
• A dental care kit, eye care kit 
 
Once the requirements for these devices are integrated into a medical care system design, 
reliability becomes a significant engineering challenge. Questions remain as to whether medical 
  
devices which were designed for terrestrial use will provide the same functionality and 
relaiability during exploration missions.  Most medical devices used in current medical 
environments on Earth have been validated by daily clinical use and have been regulated for 
their intended use by several government agencies.  These devices are regularly maintained in a 
manner which makes them cost effective, accurate, and safe.  
Mission critical hardware for space flight is designed with strict material and design 
constraints.  The current off-the-shelf medical technology used in most primary, secondary and 
tertiary medical care environments would not meet these design and test criteria, nor would it 
meet the material limitations for critical mission space hardware.  Some medical devices may 
only meet these strict requirements for mission critical reliability if they are made redundant by 
manifesting a backup capability. This would increase the mass, power, and volume of vehicle 
design.  Most commercial medical equipment is used continuously, and therefore 
durability/reliability is tested thousands of times everyday. Mission designers will need to 
combine operational experience gained from using commercial-of-the-self medical devices with 
the reliability and ruggedness of space hardware design and testing practices.   
 
Conclusion 
The primary objective in sending humans to Mars is to explore and perform science.  The 
maintenance of human health and performance, using appropriate medical care, is essential to 
meet these mission objectives.  This is particularly true for missions which, by the nature of its 
inherit hazards, place the crew at increased risk for illness and injury.  The medical support 
required for the exploration of the solar system would include a multi-tired medical prevention 
and intervention approach.  The evidence based use of tertiary prevention for treatment of 
stochastic or unpreventable illness or injury is difficult to accomplish even on remote terrestrial 
outposts where operational data is becoming abundant.  Medical planning for a surface mission 
to Mars must address the expected hazards secondary to the mission profile in addition to the 
stochastic medical events inherent in any population of healthy humans.  The 1/3 gravity 
environment enables a much simpler design of medical hardware and procedures when compared 
to the microgravity of ISS.  Nonetheless, the voyage to and from Mars will occur in a 
microgravity environment barring the deployment of large scale artificial gravity on transfer 
vehicles. Medical systems designed for these disparate gravitational fields may require unique 
  
hardware and procedural solutions to handle samples and waste under varied environmental 
conditions. 
Medical hazards for space exploration are diverse in their incidence, severity, and 
outcome.  The ability to maintain current standards of care for exploration missions over the next 
25 years will be complicated by the lead time of 5 to 10 years it takes to design, build, validate 
and certify a medical support system for flight, while terrestrial medical standards of care 
continue to evolve.  The medical support of a Moon mission in 10 years and a Mars mission in 
20 years may require a different paradigm as it pertains to maintenance of the appropriate 
medical standards of care, given that these standards advance daily on Earth.    
Most medical provider organizations rely on an evidenced-based approach to deriving 
standards of care. Exploration medicine will to some extent be able to call on the experiences of 
past and current spaceflight , in addition to advances that have occurred in medicine in extreme 
environments  However, Lunar and Mars missions may represent a “new frontier”, where we 
may find ourselves in a situation similar to the 1960’s lunar missions…. inventing a space 
medical risk mitigation strategy based on “a whole bunch of smart people thinking hard in 











Figure 1.  
Constraints must be considered in the mission optimization process including mass, power, and 
volume (MPV), and the medical capability that will be required for adequate hazard control and 
emergency procedures.  Launch weight and volume constraints exist both on Earth and for return 
from lunar and planetary missions, potentially requiring forty pounds of vehicle launch weight 
per pound of medical payload for a long duration Mars mission.  The launch phase for return 
from distant exploration destinations are even more challenging from a mass standpoint.  Thus 
the relative importance of primary and secondary prevention strategies increases as mission 
duration, distance of destinations, number of surface launches required, hazard likelihoods, and 
number of crew increase.   
 
 Table 1 - Medical Capability on Shuttle and the ISS 
  
Shuttle SOMS • Airway Subpack (Resuscitator / Ambu bag valve 
mask) 
• Trauma Subpack 
• EENT Subpack (contains general diagnostic and 
therapeutic items) and TONO-PEN Kit 
• Drug Subpack (contains oral, topical and injectable 
medications.) 
• Saline Supply Bag 
• IV Administration Subpack (plus blood pressure cuff 
used to move the IV saline fluid through the IV line) 
and one 500ml bag of saline 
• Sharps Container 
• Patient and rescuer restraints 
• Operational Bioinstrumentation System to provide the 
ability to downlink Electrocardiogram 
• Contaminant Cleanup Kit 
• Medical Accessory Kit ( storage location for all 
crewmember personal medications) 
Advanced Life 
Support Pack 
• Injectable medications 
• Intravenous fluid and administration equipment 
• Airway management equipment.   
• Blood pressure cuff 
• Stethoscope 




• Oral medications 
• Topical medications 
 • Bandages for most in-flight problems 
• Portable Clinical Blood Analyzer 
• Dental hardware 
• Minor surgical supplies 
The CMRS provides restraint, with spinal stabilization, 
for an ill or injured crewmember, while also providing 
restraint for the CMOs attending to the patient 
Crew Medical 




Multipurpose cleanup kit.  Its primary purpose is to 
protect crewmembers from contamination from toxic 




Laptop with a customized Medical Operation Software 
load.  
• Displays physiological data from exercise devices 
• Collects and stores medical data 
• Maintains medical records 
• Tool to assess crew health 
• Provides up link/down link capability 
  
 Defibrillator Provides for defibrillation, ECG and heart rate 
monitoring and analysis, and transcutaneous (external) 
pacing.   
 Respiratory 
Support Pack
Ventilates an unconscious crewmember automatically, 
provides oxygen to a conscious crewmember. 
 Blood Pressure/ 
Electrocardiograph 
Provides the capability for automated, auscultative, 
noninvasive systolic and diastolic blood pressure 
measurements and the capability to monitor and display 
heart rates/ECG waveforms on a continual basis during 




Treadmill with Vibration Isolation System • 
Resistive Exercise Device  • 
Cycle Ergometer with Vibration Isolation System • 
 
  
Table 2 - Medical Hardware Limitations for Constellation Vehicles 
Vehicle/Mission Size (inches) Mass (lbs) Role 
CEV to ISS 10x7x6  10 Treatment of minor ailments on route to ISS 
and return to earth  
LSAM Medical 
Contingency 
32x12x16 30 Portable medical gear to be able to respond 
to surface illness and injuries as required. 
Must interface with CEV 
Lunar Base 
Contingency 
16x16x8.5 16 Portable medical gear to be able to respond 
to surface illness and injuries as required. 
Must interface with LSAM and CEV 
 
  
 Table 3 – Levels of prevention 
Prevention Definition * Rationale Methods 
Primary Those measures 
“provided to 
individuals to prevent 
the onset of a targeted 
condition” 
Eliminate the hazard 
e.g. by  selecting in 
crew members without 
disease, and who have 
no symptoms of disease 
This is achieved by 
estimating the incidence and 
prevalence of pathology in 
the astronaut cohort.  
The astronaut cohort is small, 
and therefore risk data must 
be derived from observations, 
likelihoods, and severity of 
illness or injury in similar 
cohorts such as the military. 
Secondary Those measures  Protect against a hazard 
that could not be 
controlled by primary 
prevention alone such as 
the effects of reduced 
gravity on bone or 
chronic low dose 
radiation on increased 
cancer likelihood. 
During space travel there are 
root-causes to environmental 
and operational hazards 
which are not adequately 
controlled by mission design 
or other primary prevention 
strategies.  These root-causes 
need to be mitigated using 
secondary prevention such as 
load bearing exercise to 
reduce bone loss in reduced 
gravity environments.  
“that identify and treat 
asymptomatic persons 
who have already 
developed risk factors 
or preclinical disease 
but in whom the 
condition is not 
clinically apparent” 
Tertiary Those measures Tertiary prevention is 
invoked in most medical 
systems when primary 
and secondary 
prevention has failed. It 
is the least cost effective 
means of providing 
medical care in an 
extreme environment. 
Illness or injury may be due 
to an uncontrolled hazard 
harming the crew (fire), an 
ineffective countermeasure 
(decompression sickness), or 
previously undetected disease 
causing an acute illness 
requiring treatment.  The 
ability to provide tertiary 
capabilities can be 
categorized as Advanced Life 
Support care, Transitional 
care and Ambulatory care.   
“which the care for 
established disease, 
with attempts made to 
restore to highest 
function, minimize the 
negative effects of 




* Adapted from U.S. Preventative Services Task Forces’ Guide to Clinical Preventive Services 
 




Mission Suggested Capability Rationale 
I LEO < 8 days BLS + first-aid capability  All serious illness and injury will 
be evacuated to an Earth based 
DCMF. 
(STS and CEV) 
II LEO < 30 days Level I + Clinical 
diagnosis, Ambulatory 
Care, Private audio (+/- 
Video) Telemedicine 
Relatively short mission duration 
eliminates need to evaluate for 
long-term changes during the 
mission 
SST to Hubble  
 
III LEO > 30 days  Level II + Limited ACLS, 
ATLS, Minor surgical 
care, return vehicle with 
dedicated capability. 
Immediate return to Earth 
capability shall be available for 
more serious illness/injuries. 
ISS (or Lunar 
sortie) 
IV Lunar Outpost > 
30 days 
Level III + imaging and 
sustainable ACLS 
Advanced Life Support 
capability, but not the critical 
care needed after such an event 
since the evacuation vehicle(s) 
shall support Advanced Life 
Support equipment for return to 
Earth. 
V Mars Expedition 
>210 days 
Level IV + without 
immediate return to earth 
capability. Autonomous 
ALS, Basic surgical care 
and palliative care. 
Trial of therapy for patients 
requiring Advanced Life Support. 
The training and caliber of the 
primary caregiver shall be a 
physician.  Palliative care shall be 
manifested since failure of 
therapy may result may result 
permanent impairment or death.  
 
BLS – Basic Life Support 
ALS – Advanced Life Support 
ACLS – Advanced Cardiac Life Support 
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